Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17961883 | 0.85 | KDM4E (0.70) | ALDH1A1LMNAPKMSMN1; SMN2TSHR | |
| SCHEMBL5680202 | 0.85 | ALDH1A1 (0.71) | ALDH1A1PKMTP53MAPTSMN1; SMN2 | |
| SCHEMBL25967979 | 0.84 | ALDH1A1 (0.65) | ALDH1A1LMNAPKMMAPTSMN1; SMN2 | |
| SCHEMBL12310087 | 0.84 | KDM4E (0.67) | ALDH1A1LMNAPKMTP53MAPT | |
| SCHEMBL19991949 | 0.83 | LMNA (0.73) | ALDH1A1LMNATP53SMN1; SMN2TSHR | |
| SCHEMBL3970094 | 0.83 | LMNA (0.73) | ALDH1A1LMNATP53SMN1; SMN2TSHR | |
| SCHEMBL8036144 | 0.83 | LMNA (0.73) | ALDH1A1LMNATP53SMN1; SMN2TSHR | |
| SCHEMBL3974277 | 0.83 | LMNA (0.73) | ALDH1A1LMNATP53SMN1; SMN2TSHR | |
| SCHEMBL9709591 | 0.80 | ALDH1A1 (0.62) | ALDH1A1PKMTP53MAPTSMN1; SMN2 | |
| SCHEMBL5915339 | 0.77 | LSS (0.79) | ALDH1A1LMNASMN1; SMN2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2025-09-11 | — | — | US | claimed |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2024-09-05 | — | — | US | claimed |
| CN-114716390-A | Compositions and methods for treating and/or preventing necrosis of cells or tissue | ELA制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2018-11-01 | — | — | US | claimed |
| EP-3280401-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162870-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | NATHAN ILANA (IL) | 2016-10-13 | — | — | WO | claimed |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2025-09-11 | — | — | US | disclosed |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2024-09-05 | — | — | US | disclosed |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | Ela Pharma Ltd (IL) | 2024-04-02 | — | — | US | disclosed |
| CN-114716390-A | Compositions and methods for treating and/or preventing necrosis of cells or tissue | ELA制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4005569-A2 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2022-06-01 | — | — | EP | disclosed |
| CN-107690429-B | Composition for the treatment and/or prevention of necrosis of cells or tissue, specifically targeting cathepsin C and/or CELA1 and/or CELA3A and/or enzymes structurally related thereto | ELA制药有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2021-10-07 | — | — | US | disclosed |
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | ELA PHARMA LTD. (IL) | 2021-04-06 | — | — | US | disclosed |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2018-11-01 | — | — | US | disclosed |
| EP-3280401-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016162870-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | NATHAN ILANA (IL) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968185-B2 | Substituted thiazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSV, CTSA | ALDH1A1 1838/4885LMNA 229/4885PKM 2323/4885 |
| US-20240294480-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | ALDH1A1 2996/4885LMNA 199/4885PKM 3192/4885 |
| US-20180312477-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | ALDH1A1 2996/4885LMNA 199/4885PKM 3192/4885 |
| US-11945787-B2 | Substituted imidazoles for preventing and/or treating cell or tissue necrosis | CELA1, CTSA, CPA1 | ALDH1A1 944/4885LMNA 466/4885PKM 3845/4885 |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | ALDH1A1 2996/4885LMNA 199/4885PKM 3192/4885 |
| US-20210309620-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CTSA, CTSG, CELA1 | ALDH1A1 2925/4885LMNA 161/4885PKM 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.